Fig. 10From: PTD-mediated delivery of α-globin chain into Κ-562 erythroleukemia cells and α-thalassemic (HBH) patients’ RBCs ex vivo in the frame of Protein Replacement TherapyDiagrams for % positive for HbH-IBs in RBCs, derived from HbH patients (Patients 1–4), which were reduced after incubation with 10xHis-XaSITE-TAT-α-globin-HA, for 48 hBack to article page